Vertex Pharmaceuticals
VRTX
978 hedge funds and large institutions have $46.8B invested in Vertex Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 115 funds opening new positions, 398 increasing their positions, 333 reducing their positions, and 125 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 398 | Existing positions reduced: 333
6% more call options, than puts
Call options by funds: $757M | Put options by funds: $713M
0.99% less ownership
Funds ownership: 90.95% → 89.96% (-0.99%)
8% less first-time investments, than exits
New positions opened: 115 | Existing positions closed: 125
2% less funds holding
Funds holding: 999 → 978 (-21)
6% less funds holding in top 10
Funds holding in top 10: 16 → 15 (-1)
8% less capital invested
Capital invested by funds: $50.6B → $46.8B (-$3.87B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$429M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$307M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$284M |
| 4 |
JP Morgan Chase
New York
|
+$258M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$172M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$907M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$722M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$312M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$310M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$278M |
VRTX Hedge Fund Activity: Q2 2021 in Review
978 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2021, worth a combined $46.8B — down 7.6% from $50.6B a quarter earlier.
Sellers outnumbered buyers: 125 funds closed out of VRTX and 115 opened new positions — a net loss of 10 holders — while 333 trimmed existing stakes and 398 added.
The largest buyer was Loomis, Sayles & Company, adding an estimated $429M. The largest seller was Fidelity Investments, cutting an estimated $907M.
- 978 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2021, down from 999 in Q1 2021.
- Funds reported $46.8B of Vertex Pharmaceuticals stock for Q2 2021, down 7.6% quarter-over-quarter.
- 115 funds opened new Vertex Pharmaceuticals positions in Q2 2021 and 125 closed out, a net change of -10 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2021 was Loomis, Sayles & Company, an estimated $429M added.
- The largest Vertex Pharmaceuticals seller in Q2 2021 was Fidelity Investments, an estimated $907M sold.
Based on aggregated 13F filings for Q2 2021.